NCT05219500 2026-04-03
TATCIST
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT07093801 2026-02-20
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06830850 2026-01-15
A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
Atridia Pty Ltd.
Phase 1 Recruiting
NCT02975934 2025-07-25
TRITON3
pharmaand GmbH
Phase 3 Completed
NCT03641560 2025-04-08
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Phase 4 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03454750 2025-01-08
LU-PSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT03328364 2024-11-21
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Astellas Pharma Inc
Completed
NCT03776968 2024-10-23
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT03177187 2024-09-26
ACE
Institute of Cancer Research, United Kingdom
Phase 1/2 Terminated
NCT04458311 2024-04-25
ACTIon
Institute of Cancer Research, United Kingdom
Phase 1/2 Terminated
NCT05124795 2024-01-17
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Immunic AG
Phase 1 Terminated
NCT03752099 2023-09-26
To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
Veru Inc.
Phase 1/2 Terminated
NCT03658447 2023-07-28
PRINCE
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT04634344 2022-07-11
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
Dizal Pharmaceuticals
Phase 1 Terminated
NCT03042312 2021-03-24
RESIST-PC
Endocyte
Phase 2 Terminated
NCT03774056 2020-11-03
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT03778047 2020-11-03
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT02471469 2020-10-19
ILUMINATE
Radboud University Medical Center
Completed
NCT04486937 2020-07-27
mCRPC
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT02426333 2019-09-13
OPTIMUM
Radboud University Medical Center
Completed
NCT04056754 2019-08-14
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Completed
NCT02424448 2016-07-26
BIOMETHS
The Christie NHS Foundation Trust
Completed